ERYTECH PHARMA's ticker is ERYP and the CUSIP is 29604W108. A total of 4 filers reported holding ERYTECH PHARMA in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $690,000 | -52.1% | 1,314,656 | 0.0% | 0.03% | -58.6% |
| Q2 2022 | $1,440,000 | -39.8% | 1,314,656 | 0.0% | 0.07% | -27.1% |
| Q1 2022 | $2,393,000 | -22.9% | 1,314,656 | 0.0% | 0.10% | -15.0% |
| Q4 2021 | $3,103,000 | -59.1% | 1,314,656 | 0.0% | 0.11% | -61.8% |
| Q3 2021 | $7,586,000 | +19.0% | 1,314,656 | 0.0% | 0.30% | +23.8% |
| Q2 2021 | $6,376,000 | +42.7% | 1,314,656 | +110.3% | 0.24% | +42.3% |
| Q1 2021 | $4,469,000 | -27.0% | 625,000 | 0.0% | 0.17% | -30.3% |
| Q4 2020 | $6,119,000 | +56.7% | 625,000 | 0.0% | 0.24% | +13.1% |
| Q3 2020 | $3,906,000 | -25.8% | 625,000 | 0.0% | 0.21% | -34.3% |
| Q2 2020 | $5,263,000 | +57.7% | 625,000 | 0.0% | 0.32% | +4.2% |
| Q1 2020 | $3,338,000 | -26.6% | 625,000 | 0.0% | 0.31% | -9.9% |
| Q4 2019 | $4,550,000 | +64.0% | 625,000 | 0.0% | 0.34% | +18.2% |
| Q3 2019 | $2,775,000 | -38.1% | 625,000 | 0.0% | 0.29% | -40.3% |
| Q2 2019 | $4,481,000 | -5.7% | 625,000 | 0.0% | 0.49% | -8.1% |
| Q1 2019 | $4,750,000 | +12.2% | 625,000 | 0.0% | 0.53% | -3.8% |
| Q4 2018 | $4,234,000 | -22.3% | 625,000 | 0.0% | 0.55% | +15.4% |
| Q3 2018 | $5,450,000 | -24.4% | 625,000 | 0.0% | 0.48% | -32.0% |
| Q2 2018 | $7,213,000 | -45.0% | 625,000 | 0.0% | 0.70% | -47.1% |
| Q1 2018 | $13,125,000 | -4.6% | 625,000 | 0.0% | 1.33% | -19.8% |
| Q4 2017 | $13,763,000 | – | 625,000 | – | 1.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|